JNCE Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2023 @ 23:00):

Stats
Šios dienos apimtis	11.60M
Vidutinė apimtis	3.47M
Rinkos kapitalizacija	98.95M
EPS	$0 ( 2024-03-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.958
ATR14	$0.0820 (4.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-03	Concentra Biosciences, Llc	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Buy	10 000	Common Stock
2023-05-03	Tang Kevin C	Sell	5 300 087	Common Stock
2023-05-03	Concentra Biosciences, Llc	Buy	0	Common Stock
2023-05-03	Salter-cid Luisa	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-96.64
Last 98 transactions
Buy: 1 025 987 \| Sell: 8 913 091

Tūris Koreliacija

Ilgas: -0.01 (neutral)

Trumpas: -0.19 (neutral)

Signal:(59.515) Neutral

Jounce Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVAC	0.941
BLPH	0.916
TZPSU	0.914
TZPS	0.913
ARRW	0.911
NBST	0.909
EBACU	0.908
MTSL	0.908
ARDX	0.903
KBAL	0.902

10 Labiausiai neigiamai susiję koreliacijos
LWAC	-0.964
FRBA	-0.956
AMAL	-0.953
CCB	-0.953
CVBF	-0.95
RBB	-0.946
FBMS	-0.946
MYFW	-0.944
INDB	-0.942
CBAN	-0.941

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Jounce Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.07
( neutral )

0.34
( neutral )

0.58
( weak )

0.63
( weak )

-0.62
( weak negative )

-0.09
( neutral )

Jounce Therapeutics Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$82.00M
Bruto pelnas:	$82.00M (100.00 %)
EPS:	$-0.990

FY	2022
Pajamos:	$82.00M
Bruto pelnas:	$82.00M (100.00 %)
EPS:	$-0.990

FY	2021
Pajamos:	$26 907.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.00182

FY	2020
Pajamos:	$62.34M
Bruto pelnas:	$62 339.00 (0.10 %)
EPS:	$-1.240

Financial Reports:

No articles found.

Jounce Therapeutics Inc

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.